| |
| |
|
| Insider
Information: |
Thackray Helen M. |
| Relationship: |
Director |
| City: |
Gaithersburg |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
425,254 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,307,607 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
425,254 |
|
|
| Total
Value |
$1,307,607 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Glycomimetics Inc |
GLYC |
SVP Clinical Developme... |
2021-01-20 |
183,115 |
|
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Chief R&D Officer |
2024-03-31 |
242,139 |
2021-03-31 |
0 |
Premium* |
|
|
Immunogen Inc |
IMGN |
Director |
2024-02-12 |
0 |
2023-06-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2024-03-31 |
4 |
D |
$5.08 |
$38,227 |
D/D |
(7,525) |
242,139 |
0 |
- |
|
| IMGN |
Immunogen Inc |
Director |
– • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,074) |
0 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-12-29 |
4 |
A |
$29.65 |
$7,472 |
D/D |
252 |
3,074 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$33,759 |
D/D |
(5,580) |
249,664 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$19,489 |
D/D |
(3,031) |
255,244 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
51,000 |
258,275 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-09-29 |
4 |
A |
$15.87 |
$7,491 |
D/D |
472 |
2,822 |
0 |
- |
|
| IMGN |
Immunogen Inc |
|
– • – |
2023-06-30 |
4 |
A |
$18.87 |
$7,491 |
D/D |
397 |
2,350 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2023-04-03 |
4 |
AS |
$8.29 |
$58,030 |
D/D |
(7,000) |
207,275 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
214,275 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2022-12-15 |
4 |
AS |
$10.89 |
$34,031 |
D/D |
(3,125) |
133,275 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2022-04-01 |
4 |
AS |
$16.20 |
$123,120 |
D/D |
(7,600) |
136,400 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
44,000 |
144,000 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Chief R&D Officer |
• • – |
2021-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
SVP Clinical Development, CMO |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
34,500 |
183,115 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
SVP Clinical Development, CMO |
• – – |
2017-12-08 |
4 |
AS |
$15.01 |
$30,020 |
D/D |
(2,000) |
148,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
SVP Clinical Development, CMO |
• – – |
2017-09-18 |
4 |
AS |
$13.00 |
$26,000 |
D/D |
(2,000) |
150,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
SVP Clinical Development, CMO |
• – – |
2017-05-25 |
4 |
AS |
$15.57 |
$31,140 |
D/D |
(2,000) |
152,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
SVP Clinical Development, CMO |
• – – |
2017-05-19 |
4 |
AS |
$12.14 |
$24,280 |
D/D |
(2,000) |
154,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMO |
• – – |
2016-10-03 |
4 |
AS |
$7.00 |
$28,001 |
D/D |
(4,000) |
156,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMO |
• – – |
2016-07-20 |
4 |
AS |
$8.00 |
$16,000 |
D/D |
(2,000) |
160,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMO |
• – – |
2016-07-06 |
4 |
AS |
$6.68 |
$45,397 |
D/D |
(6,796) |
162,615 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMO |
• – – |
2016-07-05 |
4 |
AS |
$7.01 |
$71,053 |
D/D |
(10,136) |
169,411 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMO |
• – – |
2016-07-01 |
4 |
AS |
$7.40 |
$37,503 |
D/D |
(5,068) |
179,547 |
0 |
- |
|
| GLYC |
Glycomimetics Inc |
VP Clinical Development, CMOOf |
• – – |
2014-01-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
184,615 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
